Pneumocandin B0CAS# 135575-42-7 |
- PF-562271
Catalog No.:BCC3674
CAS No.:717907-75-0
- TAE226 (NVP-TAE226)
Catalog No.:BCC3885
CAS No.:761437-28-9
- PF-573228
Catalog No.:BCC4496
CAS No.:869288-64-2
- PF-00562271
Catalog No.:BCC3684
CAS No.:939791-38-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 135575-42-7 | SDF | Download SDF |
| PubChem ID | 72475 | Appearance | Powder |
| Formula | C50H80N8O17 | M.Wt | 1065.21 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| SMILES | CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CC(=O)N)O)O)O)O | ||
| Standard InChIKey | DQXPFAADCTZLNL-YSHLLHMASA-N | ||
| Standard InChI | InChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30+,31-,32-,33-,34-,35+,38-,39-,40-,41-,42-,43-,46+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Pneumocandin B0 Dilution Calculator
Pneumocandin B0 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.9388 mL | 4.6939 mL | 9.3878 mL | 18.7756 mL | 23.4696 mL |
| 5 mM | 0.1878 mL | 0.9388 mL | 1.8776 mL | 3.7551 mL | 4.6939 mL |
| 10 mM | 0.0939 mL | 0.4694 mL | 0.9388 mL | 1.8776 mL | 2.347 mL |
| 50 mM | 0.0188 mL | 0.0939 mL | 0.1878 mL | 0.3755 mL | 0.4694 mL |
| 100 mM | 0.0094 mL | 0.0469 mL | 0.0939 mL | 0.1878 mL | 0.2347 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nav1.7 inhibitor
Catalog No.:BCC4191
CAS No.:1355631-24-1
- Schisanlignone A
Catalog No.:BCN3628
CAS No.:135557-67-4
- Cudraxanthone L
Catalog No.:BCN6187
CAS No.:135541-40-1
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
- Mutant IDH1-IN-1
Catalog No.:BCC6403
CAS No.:1355326-21-4
- 2,3-Dihydro-12,13-dihydroxyeuparin
Catalog No.:BCN7189
CAS No.:135531-75-8
- ML 190
Catalog No.:BCC6308
CAS No.:1355244-02-8
- CYM 50260
Catalog No.:BCC6259
CAS No.:1355026-60-6
- Cabazitaxel intermediate
Catalog No.:BCN7432
CAS No.:1354900-65-4
- Araliadiol
Catalog No.:BCC8835
CAS No.:1354638-93-9
- Strontium Ranelate
Catalog No.:BCC3858
CAS No.:135459-87-9
- Rehmapicrogenin
Catalog No.:BCN8507
CAS No.:135447-39-1
- Parsonsianidine
Catalog No.:BCN2109
CAS No.:135601-81-9
- Fmoc-D-His(Trt)-OH
Catalog No.:BCC3504
CAS No.:135610-90-1
- Coccineone B
Catalog No.:BCN6464
CAS No.:135626-13-0
- CP 80633
Catalog No.:BCC7463
CAS No.:135637-46-6
- 17-Methylparsonsianidine
Catalog No.:BCN2093
CAS No.:135637-68-2
- Fmoc-Cha-OH
Catalog No.:BCC3160
CAS No.:135673-97-1
- Narchinol B
Catalog No.:BCN7796
CAS No.:1356822-09-7
- ent-3-Oxokaurane-16,17-diol
Catalog No.:BCN6188
CAS No.:135683-73-7
- AZD-3463
Catalog No.:BCC3907
CAS No.:1356962-20-3
- HG-14-10-04
Catalog No.:BCC5392
CAS No.:1356962-34-9
- N-Acetylglycyl-D-glutamic acid
Catalog No.:BCC6634
CAS No.:135701-69-8
- c-Met inhibitor 1
Catalog No.:BCC1488
CAS No.:1357072-61-7
Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0.[Pubmed:17343416]
J Org Chem. 2007 Mar 30;72(7):2335-43.
A novel three-step synthesis of the highly functionalized antifungal agent CANCIDAS (caspofungin acetate, 2) is described, starting from the natural product Pneumocandin B0 (1). The highlights of the synthesis include a stereoselective formation of a phenylthioaminal, a remarkable chemoselective, high-yielding, one-step borane reduction of a primary amide, and a stereoselective substitution of the phenylthioaminal with ethylenediamine producing 2 in a 45% overall yield.
Pneumocandin B0-imprinted Polymer Using Surface-imprinting Technique for Efficient Purification of Crude Product.[Pubmed:27682395]
Anal Sci. 2016;32(9):923-30.
In this work, we prepared surface molecularly imprinted polymer (MIP) for selective recognition of Pneumocandin B0 (PNB0). Methacrylic acid (MAA) was first grafted onto silica gel particles (SiO2) in the manner of "grafting from" by using 3-methacryloxypropyl trimethoxysilane as intermedium, and then PNB0 molecules were imprinted on the surface of the obtained particles in the presence of ethylene glycol diglycidyl ether as the cross-linker. The prepared MIP-PMAA/SiO2 was characterized by scanning electron microscopy, Fourier transform infrared spectroscopy and thermo-gravimetric analysis, which confirmed the successful grafting of MAA onto SiO2 and the grafting degree was calculated to be 12.50 wt%. The binding properties of the products were investigated and it is found that the binding process of PNB0 followed the pseudo-second-order kinetic model. The as-prepared material also displays relatively quick adsorption kinetics and decent recognition affinity toward the template over its structurally related compound.
Preparation and evaluation of novel stationary phases for improved chromatographic purification of pneumocandin B0.[Pubmed:16257000]
J Chromatogr A. 2006 Jan 6;1101(1-2):204-13.
Preparation and evaluation of a number of stationary phases for improved chromatographic purification of Pneumocandin B0, a key intermediate in the synthesis of the antifungal agent, Cancidas, has led to the identification of several materials with potential for improved performance.
Engineering of Glarea lozoyensis for exclusive production of the pneumocandin B0 precursor of the antifungal drug caspofungin acetate.[Pubmed:25527531]
Appl Environ Microbiol. 2015 Mar;81(5):1550-8.
Pneumocandins produced by the fungus Glarea lozoyensis are acylated cyclic hexapeptides of the echinocandin family. Pneumocandin B0 is the starting molecule for the first semisynthetic echinocandin antifungal drug, caspofungin acetate. In the wild-type strain, Pneumocandin B0 is a minor fermentation product, and its industrial production was achieved by a combination of extensive mutation and medium optimization. The pneumocandin biosynthetic gene cluster was previously elucidated by a whole-genome sequencing approach. Knowledge of the biosynthetic cluster suggested an alternative way to produce exclusively Pneumocandin B0. Disruption of GLOXY4, encoding a nonheme, alpha-ketoglutarate-dependent oxygenase, confirmed its involvement in l-leucine cyclization to form 4S-methyl-l-proline. The absence of 4S-methyl-l-proline abolishes pneumocandin A0 production, and 3S-hydroxyl-l-proline occupies the hexapeptide core's position 6, resulting in exclusive production of Pneumocandin B0. Retrospective analysis of the GLOXY4 gene in a previously isolated Pneumocandin B0-exclusive mutant (ATCC 74030) indicated that chemical mutagenesis disrupted the GLOXY4 gene function by introducing two amino acid mutations in GLOXY4. This one-step genetic manipulation can rationally engineer a high-yield production strain.
